The incidence was highest in Peutz-Jeghers syndrome patients (2/9, 22%) and CDKN2A mutation carriers (7/96, 7%), confirming the findings by Vasen et al. 20 The high PDAC incidence rates within these groups support the recommendation that these specific mutation carriers are favourable candidates for surveillance. This evidence concerns the gene CDKN2A and Peutz-Jeghers syndrome.